海外の治験の状況「1」での検索結果
1993件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- Extension study to evaluate the Safety of CB-03-01 1% cream applied twice daily in subjects with Acne Vulgaris
- Facial and truncal acne vulgaris MedDRA version: 19.0 Level: LLT Classification code 10000519 Term: Acne vulgaris System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Bulgaria, Poland, Serbia, United States
- 2016-04-18
Authorised
- A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies
- Potential subjects include those with advanced or metastatic malignancies who are ineligible for all therapeutic options that are standard of care or known to confer clinical benefit, or who refuse these treatments. MedDRA version: 20.0 Level: LLT Classification code 10048683 Term: Advanced cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Belgium, Netherlands, United States
- 2017-06-30
Authorised
- Prévention de la transmission du VIH-1 de la mère à l’enfant sans utilisation d’analogue nucléosidique - PRIMEVA
- Vertical Infection Transmission MedDRA version: 9.0 Level: LLT Classification code 10047337
- France
- 2007-01-12
Authorised
- Efecto antiinflamatorio bronquial del tratamiento sustitutivo en pacientes con déficit de alfa-1 antitripsina - Pharmacodynamics of AAT
- El déficit de alfa-1-antitripsina (AAT) es una enfermedad hereditaria de expresión autosómica recesiva que se caracteriza por concentraciones anormalmente reducidas de AAT en sangre, lo que comporta en su forma homocigótica, un elevado riesgo de aparición de enfisema pulmonar precoz, y en determinadas ocasiones enfermedad hepática (1). MedDRA version: 9 Level: PT Classification code 10001806 Term: Alpha-1 anti-trypsin deficiency
- Spain
- 2008-05-29
Authorised
- A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies
- Advanced Malignancies MedDRA version: 20.0 Level: LLT Classification code 10048683 Term: Advanced cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Denmark, United States
- 2017-01-20
Authorised
- A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
- Subjects with relapsed or refractory advanced or metastatic malignancies. MedDRA version: 20.0 Level: LLT Classification code 10048683 Term: Advanced cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Belgium, France, United States
- 2017-12-21
Authorised
- A Phase 1/2 Open-label Study in Patients with Arginase I Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous AEB1102
- Arginase 1 deficiency Hyperargininemia MedDRA version: 20.0 Level: PT Classification code 10062695 Term: Arginase deficiency System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Canada, Portugal, United Kingdom, United States
- 2018-01-12
Authorised
- A pilot study in the use of the GLP-1 agonist liraglutide in the treatment of short bowel
- Intestinal failure with an underlying aetiology of short bowel MedDRA version: 20.1 Level: PT Classification code 10049416 Term: Short-bowel syndrome System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- United Kingdom
- 2018-05-08
Authorised
- Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes - MRC-ILA-HEART study
- We wish to investigate Acute coronary syndromes (ACS). These are caused by blockages in the main arteries that supply the heart as a result of a process called atherosclerosis. These blockages prevent blood flow down the artery and therefore prevent the heart muscle getting the blood and oxygen that it needs to survive and function. They account for 15% of all deaths in the UK and are associated with considerable long term consequences among survivors. MedDRA version: 8.1 Level: PT Classification code 10051592 Term: Acute coronary syndrome
- United Kingdom
- 2008-02-20
Authorised
- Effect of the GLP-1 analogue liraglutide on intragastric pressure and satiation during nutrient drink infusion.
- healthy volunteers no medical condition; drugs will be studied because they are known to influence gastric motility.
- Belgium
- 2010-12-16
